Blog von Dr. med. Lothar M. Kirsch / 祁建德 // Poetry / Travels / Languages / Rheumatic Diseases / Tea
Friday, December 21, 2012
Cetrorelix at the ACR 2012 in Washington
Cetrorelix is a gonadotropin-releasing hormone antagonist (GnRH antagonist). I expected some new results. Older results here: http://rheumatologe.blogspot.de/2012/07/cetrorelix-at-eular-2012.html
And there are new results! A. Kass and colleagues looked at cetrorelix in a proof-of concept study and it demonstrates efficacy in patients with active rheumatoid arthritis (Abstract No. 834). Their results showed that “more patients on cetrorelix achieved ACR20 responses (40% vs 18%; p_0.015)”. Nothing that makes drop off your chair, but at least a result to work on. Conclusions included: “Larger, long-term studies on the efficacy and safety of GnRH antagonists in RA patients are warranted.”
No other abstract on cetrorelix! It doesn’t sound like a success story, but it’s interesting enough to be followed. We’ll just have to wait for further results.
19.06.2013
Nothing at the EULAR 2013 Meeting in Madrid.
Labels:
ACR2012,
Cetrorelix,
RA,
Rheumatoid Arthritis
Brodalumab at the ACR 2012 in Washington
More on brodalumab and the EULAR 2013 at:
http://rheumatologe.blogspot.de/2013/06/brodalumab-at-eular-2013.html
Brodalumab targets interleukin-17 (IL-17) and is therefore much like ixekizumab, which hasn’t been presented at the 2012 ACR meeting. Ixekizumab is studied in chronic plaque psoriasis as shown in this article of the New England Journal of Medicine: http://www.nejm.org/doi/full/10.1056/NEJMoa1109997. Back to brodalumab.
Karel Pavelka and collaegues looked at safety, tolerability, and efficacy of brodalumab (AMG 827) in rheumatoid arthritis and an inadequate response to Methotrexate (Abstract No. 831), but the preliminary results do not support further evaluation of brodalumab as a treatment for RA.
M.A. Curchill and collaegues presented "A Phase Ib Multiple Ascending Dose Study Evaluating Safety, Pharmacokinetics, and Early Clinical Response of Brodalumab (AMG 827), a Human Anti-Interleukin 17 Receptor (IL-17R) Antibody, in Rheumatoid Arthritis" (Abstract No. 1294). “Conclusions about efficacy cannot be reached given the study design.”
I think brodalumab is a dead end for rheumatoid arthritis though it might be useful in other diseases.
ASP015K at the ACR 2012 in Washington
I've just written a blogpost concerning the data from EULAR 2013, which isn't as positive as the one below: http://rheumatologe.blogspot.de/2013/06/asp015k-at-eular-2013-meeting.html
"ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid arthritis (RA) and other autoimmune diseases."
T. Zhu et al. presented: "Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis" (Abstract No. 1322). The study had two parts: 1. In vitro experiments on the “inhibitory potency of ASP015K on human multidrug resistance-associated protein 2/4 (MRP2/4) and organic anion transporter 1/3 (OAT1/3).” And a phase 1 study, which was open-labeled and single-sequenced, “to confirm the in vivo effect of ASP015K on the PK of MTX, a substrate of MRP2/4 and OAT1/3.” Conclusions: " Coadministration of ASP015K and MTX was well tolerated in this short-term study exhibiting no clinically significant effect on the PK profile of either drug. Efficacy and safety of ASP015K/MTX combination therapy is being assessed in ongoing phase 2 trials in RA patients."
According to the design of the study there wasn’t more to be expected.
Shunji Yamazaki and colleagues presented a seond study (Abstract No. 2084): “ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats.” They could show in this rat model, that ASP015K “potently inhibits human JAK enzymes with moderate selectivity against JAK1/3 over JAK2/2, which may translate to less hematological side effects observed in the clinic such as anemia.” Further conclusions: “The data suggests that ASP015K has the potential to reduce clinical signs and symptoms as well as prevent disease progression in RA patients warranting further clinical investigation.”
ASP015K is an interesting small molecule as it may be efficacious against rheumatoid arthritis with less adverse events when compared to other small molecules. The data is preliminary and there’s still a long way to go. It would be nice, if Astellas Pharma could give the compound a name. Good luck from my side!
Labels:
ACR2012,
ASP015K,
RA,
Rheumatoid Arthritis,
small molecules
Gedanken zum heutigen Weltuntergang
Ich begann den heutigen Morgen (21.12.2012) mit Iron Maiden. Ein wenig Weltuntergang hängt dieser Musik schon an, aber ich freute mich, denn ich hatte die Gruppe schon eine Weile nicht mehr gehört.
Ich bin Pendler. Die Autobahn sah nicht nach Weltuntergang aus. Da waren die Raser, die unüberlegten LKW-Fahrer, die plötzlich ausscherten, die sturen Mittelspurfahrer und all die anderen, neben denen man jeden Morgen auswacht. Im Radio spielte man Tempo di Gavotta von Arcangelo Corelli und Nun singet und seid froh von Michael Praetorius, also Musik, die alles andere als den Weltuntergang symbolisiert.
Martin Luther sagte es zwar nicht, aber ihm wurde der Satz zugeschrieben: "Wenn ich wüsste, dass morgen der jüngste Tag wäre, würde ich heute noch ein Apfelbäumchen pflanzen." (zitiert nach Wikiquote) Ich habe gestern kein Bäumchen gepflanzt, aber ein aufgestellt, denn ich habe eine Azalee (? – die bereits auf Twitter bekannte Schwester Waltraud bestimmte die Pflanze als Azalee) geschenkt bekommen. Neben dem Yggdrasil ähnlichen Gewächs daneben steht die Pflanze für den Neuanfang, während Yggdrasil für den Fortbestand unseres Universum stehen soll ... Stopp! Wenn ich jetzt nicht aufpasse, schweife ich zu sehr aber, bringe hier noch die Edelsteinminen in Südafrika und die Ananaszüchter in der Arktis unter.
Wahrscheinlich benötigen wir ab und zu einen Hinweis auf die Apokalypse (hat wahrscheinlich nichts mit der Meernymphe Kalypso zu tun), auch wenn sie die Erde erst in einigen Milliarden Jahren betreffen wird. Interessanterweise ist das apokalyptische Buch des Neuen Testaments (Offenbahrung) dasjenige, dessen Texttreue am wenigsten angezweifelt wird. Daraus sollte man aber nicht den Schluss ziehen, dass alle Chaosmeldungen in der Boulevardpresse wahr und wirklich wären. Und da kommen wir zu unserem Maya-Weltuntergang. Der betreffende Kalender sagt überhaupt nicht über ein Weltende. Man nimmt an, dass der Katastrophenfilm 2012 von Roland Emmerich viel dazu beigetragen hat, dass sich die Mär vom Weltuntergang verbreitete.
In Köln heißt es: „Et kütt wie et kütt.“ Und: „Et hätt noch emmer jot jejange.“
Wie werde ich den Weltuntergang heute erleben? Ich werde weiter arbeiten und manchmal unter Twitter nachschauen, was sonst so geschieht.
Thursday, December 20, 2012
Carpe Diem Haiku Early Plum Blossoms
Creeping cold
Early plum blossoms perish
Shop of plastic flowers
Still winter
Among the plum blossoms
A little snow
Winter is going
Early plum blossoms
A chorus of birds
Yesterday still
Storm and snow
Welcome plum blossoms
http://chevrefeuillescarpediem.blogspot.de/
Carpe Diem Haiku Fireplace
Mist rise above the field
Potato fire in the evening
Reminiscing summer
Red embers
Keep the fire going
And wine to salute
Sarilumab at the ACR 2012 in Washington
Sarilumab, another anti-IL-6 monoclonal antibody, has already been in a phase 2 study in 2011, what’s new? More than presented at the EULAR 2012? http://rheumatologe.blogspot.de/2012/06/sarilumab-news-from-eular-2012.html
M. C. Genovese and colleagues presented a study on sarilumab in moderate to severe rheumatoid arthritis and looked at improvements of hemoglobin levels (Abstract No. 1320). Conclusion: “Sarilumab treatment for RA over 12 weeks resulted in significant improvements in hemoglobin relative to placebo.” Very good, but do we use biologics to treat haemoglobin levels in our RA patients?
Pavel Belomestnov and colleagues found a substantial reductions in acute phase reactants (Abstract No. 1337). Sarilumab “showed substantial reductions in acute phase reactants relative to placebo.” DAS28, CDAI, SDAI, ACR20-70?
And that’s all! Oops! I’m inclined to give advice to share holders, but I´m a total dummy concerning stock markets. Where are the final results of the phase 2 study? Isn’t there any phase 3 study? OK, lets wait for the 2013 meetings!
Subscribe to:
Posts (Atom)


